ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Up 70.1% in March

ReShape Lifesciences Inc. (NASDAQ:RSLS) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 729,300 shares, a growth of 70.1% from the March 15th total of 428,700 shares. Based on an average trading volume of 807,600 shares, the days-to-cover ratio is currently 0.9 days. Approximately 3.5% of the shares of the company are short sold.

ReShape Lifesciences Stock Performance

NASDAQ:RSLS remained flat at $0.16 during trading hours on Friday. The company’s stock had a trading volume of 199,442 shares, compared to its average volume of 414,535. ReShape Lifesciences has a one year low of $0.14 and a one year high of $4.10. The stock has a fifty day moving average price of $0.17 and a 200 day moving average price of $0.23.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RSLS. Armistice Capital LLC acquired a new position in shares of ReShape Lifesciences during the 3rd quarter worth approximately $64,000. Sabby Management LLC acquired a new position in shares of ReShape Lifesciences during the 1st quarter worth approximately $192,000. Renaissance Technologies LLC acquired a new position in shares of ReShape Lifesciences during the 2nd quarter worth approximately $26,000. BlackRock Inc. raised its stake in shares of ReShape Lifesciences by 200,252.9% during the 1st quarter. BlackRock Inc. now owns 34,060 shares of the medical device company’s stock worth $88,000 after buying an additional 34,043 shares during the period. Finally, State Street Corp acquired a new position in shares of ReShape Lifesciences during the 1st quarter worth approximately $33,000. 22.06% of the stock is owned by institutional investors and hedge funds.

About ReShape Lifesciences

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation.